Table 1.
Baseline characteristics of the studied population. Data are presented as median (range) for continuous variables and as frequency (%) for categorical variables. Bold values denote statistical significance at the p < 0.05 level.
| All Subjects (n = 146) |
HCV Mono-Infected (n = 55) |
HCV/HIV Co-Infected (n = 91) |
HCV vs. HCV/HIV P |
Local Laboratory NR |
|
|---|---|---|---|---|---|
| Sex, n (M, F) | 73 (50), 73 (50) | 22 (40), 33 (60) | 51 (56), 40 (44) | 0.060 | - |
| Ethnicity, n (Caucasian, other) | 143 (98), 3 (2) 1 | 55 (100), 0 (0) | 88 (97), 3 (3) 1 | 0.317 | - |
| Risk factor for HCV ± HIV acquisition, n (IVDU, sex, transfusion, other/not known) | 73 (50), 4 (19), 3 (2), 33 (29) | 15 (27), 4 (7), 3 (6), 33 (60) | 58 (64), 24 (26), 0 (0), 9 (10) | <0.001 | - |
| Age, years | 59 (54–71) | 71 (57–80) | 57 (53–62) | <0.001 | - |
| Liver elastography, KPa 2 | 7.6 (5.9–13.1) | 8.5 (5.8–15.4) | 7.3 (5.9–10.0) | 0.522 | <5.0 |
| HCV RNA, ×103 IU/mL 2 | 868 (320–2396) | 782 (272–2912) | 885 (385–2235) | 0.841 | negative |
| HCV genotype, n (1a, 1b, 2, 3, 4) 3 |
52 (36), 25 (17), 37 (25), 21 (14), 11 (8) | 20 (36), 8 (15), 13 (24), 10 (18), 4 (7) | 32 (35), 17 (19), 24 (26), 11 (12), 7 (8) | 0.853 | - |
| HIV RNA, copies/mL 4 | - | - | 0 (0–0) | N/A | negative |
| White blood cells, n × 109/L | 5.18 (4.23–6.28) | 5.11 (4.08–6.05) | 5.78 (4.69–7.55) | 0.134 | 4.50–11.00 |
| CD4+ lymphocytes, n × 109/L 4 | - | - | 0.37 (0.27–0.86) | N/A | 0.49–1.70 |
| Platelets, n × 109/L | 199 (83–233) | 182 (85–179) | 202 (161–233) | <0.001 | 150–450 |
| AST, IU/L | 45 (26–98) | 60 (37–140) | 15 (13–18) | <0.001 | 0–40 |
| ALT, IU/L | 43 (22–103) | 69 (33–119) | 20 (16–23) | <0.001 | 0–40 |
| Total bilirubin, mg/dL | 0.8 (0.6–1.1) | 0.8 (0.6–1.1) | 0.5 (0.4–0.9) | 0.003 | 0.30–1.20 |
| Creatinine, mg/dL | 0.77 (0.64–0.90) | 0.80 (0.70–0.90) | 0.77 (0.64–0.90) | 0.992 | 0.60–1.10 |
| INR, Units | 0.9 (0.9–1.1) | 1.1 (1.0–1.2) | 1.0 (0.9–1.1) | <0.001 | 0.80–1.20 |
| Albumin, g/L | 39 (36–43) | 38 (35–41) | 45 (42–47) | <0.001 | 34–48 |
| MELD, score | 7 (6–8) | 7 (6–8) | 6 (6–7) | 0.059 | - |
| SVR after previous HCV treatments, n | 43 (29) | 13 (23) | 30 (33) | 0.231 | - |
| Current HIV therapy, n 4,5 | - | - | 91 (100) | N/A | - |
| Current or past HIV therapies with concomitant anti-HBV effect, n 4,6 | - | - | 91 (100) | N/A | - |
Abbreviations: alanine transaminase (ALT); aspartate transaminase (AST); bictegravir (BIC); cabotegravir (CAB); cobicistat booster (COBI); darunavir (DRV); dolutegravir (DTG); emtricitabine (FTC); hepatitis B virus (HBV); hepatitis C virus (HCV); human immunodeficiency virus (HIV); international normalized ratio (INR); intravenous drug user (IVDU); lamivudine (3TC); model for end-stage liver disease (MELD); normal range (NR); not applicable (N/A); raltegravir (RAL); rilpivirine (RPV); ritonavir booster (r); sustained virological response (SVR); tenofovir alafenamide (TAF); tenofovir disoproxil fumarate (TDF). 1 1 Black, 1 Asian, 1 Hispanic subject. 2 For the 103 patients who were HCV-RNA positive when entering the study. 3 For all patients, including the 43 subjects who achieved SVR before entering the study. 4 For the 91 HCV/HIV positive patients. 5 BIC/FTC/TAF (n = 24), 3TC/DTG (n = 18), RAL/DRV/COBI (n = 13), DTG/DRVr (n = 8), TAF/FTC/DRV/COBI (n = 7), DTG/RPV (n = 6), DTG/DRV/COBI (n = 6), CAB/RPV (n = 5), TDF/FTC/RPV (n = 4). 6 Including one or more of the following ones: 3TC, TDF, TAF, FTC.